Medpace (NASDAQ:MEDP) and Intrexon (NASDAQ:XON) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

Insider and Institutional Ownership

76.7% of Medpace shares are owned by institutional investors. Comparatively, 75.9% of Intrexon shares are owned by institutional investors. 24.2% of Medpace shares are owned by insiders. Comparatively, 44.0% of Intrexon shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Medpace and Intrexon’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Medpace 10.49% 17.16% 10.20%
Intrexon -363.14% -26.52% -15.07%

Earnings & Valuation

This table compares Medpace and Intrexon’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Medpace $704.59 million 3.17 $73.18 million $2.59 24.08
Intrexon $160.57 million 7.46 -$509.34 million ($1.37) -5.44

Medpace has higher revenue and earnings than Intrexon. Intrexon is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Medpace has a beta of 1.56, indicating that its share price is 56% more volatile than the S&P 500. Comparatively, Intrexon has a beta of 2.24, indicating that its share price is 124% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Medpace and Intrexon, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medpace 1 4 2.80
Intrexon 1 1 2.50

Medpace presently has a consensus price target of $58.00, suggesting a potential downside of 7.02%. Intrexon has a consensus price target of $25.00, suggesting a potential upside of 235.57%. Given Intrexon’s higher possible upside, analysts plainly believe Intrexon is more favorable than Medpace.

Summary

Medpace beats Intrexon on 10 of the 14 factors compared between the two stocks.

About Medpace

Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas. Its drug development services include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is headquartered in Cincinnati, Ohio.

About Intrexon

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms. The company also provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of any flavor-altering chemical or antioxidant additives; commercial aquaculture products; genetic preservation and cloning technologies; genetically engineered swine for medical and genetic research; and artwork, children’s toys, and novelty goods that are derived from living organisms or enabled by synthetic biology. It serves health, food, energy, environment, and consumer markets. Intrexon Corporation has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; S & I Ophthalmic, LLC; OvaXon, LLC; Intrexon Energy Partners, LLC; Persea Bio, LLC; Ares Trading S.A.; Intrexon Energy Partners II, LLC; Intrexon T1D Partners, LLC; AquaBounty Technologies, Inc.; Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.



Receive News & Ratings for Medpace Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Medpace and related companies with MarketBeat.com’s FREE daily email newsletter.



READ SOURCE

READ  Texas Tech President announces review of university admissions process - KCBD